We have developed methods for using DNA array technology to probe the entire transcriptome to determine the RNA-binding specificity of ligands. Two methods were investigated. In the first method, the RNA-binding aminoglycoside antibiotic tobramycin was covalently linked to magnetic beads. The beads were bound to human liver mRNA and washed, and specifically bound RNA was eluted, amplified, and analyzed with DNA array technology. A small number of genes were found to bind specifically to the tobramycin beads. In the second method, the aminoglycoside ligand was added directly to the array hybridization reaction, and the signal was compared with a control experiment in the absence of ligand. The aminoglycosides were found to interfere with a small percentage of all hybridization events. These methods differ from traditional DNA array experiments in that the readout is a direct measure of the interaction between mRNA and a ligand, rather than an indirect measure of effect on expression. We expect that the results will lead to the discovery of new aminoglycosidebinding RNA motifs and may also have relevance toward understanding and overcoming the side effects observed with these antibiotics in the clinic.
We have developed methods for using DNA array technology to probe the entire transcriptome to determine the RNA-binding specificity of ligands. Two methods were investigated. In the first method, the RNA-binding aminoglycoside antibiotic tobramycin was covalently linked to magnetic beads. The beads were bound to human liver mRNA and washed, and specifically bound RNA was eluted, amplified, and analyzed with DNA array technology. A small number of genes were found to bind specifically to the tobramycin beads. In the second method, the aminoglycoside ligand was added directly to the array hybridization reaction, and the signal was compared with a control experiment in the absence of ligand. The aminoglycosides were found to interfere with a small percentage of all hybridization events. These methods differ from traditional DNA array experiments in that the readout is a direct measure of the interaction between mRNA and a ligand, rather than an indirect measure of effect on expression. We expect that the results will lead to the discovery of new aminoglycosidebinding RNA motifs and may also have relevance toward understanding and overcoming the side effects observed with these antibiotics in the clinic.
aminoglycoside-RNA interactions
A minoglycosides are among the most commonly used broadspectrum antibiotics in the clinic. Since the initial discovery of streptomycin in 1944, a series of aminoglycoside antibiotics, including kanamycin, neomycin B, gentamicin, and tobramycin have been successfully introduced as treatments for serious systemic infections and have been used for a variety of topical applications.
The origin of the bactericidal activity of aminoglycosides has been extensively investigated and is due to binding to the bacterial ribosome (1) . Aminoglycosides bind specifically to the 16S rRNA, near the mRNA decoding site. This binding decreases the fidelity of protein translation by lowering the energetic cost of a conformational transition in the ribosome that is required for the discrimination between near-cognate and cognate tRNAs (2) (3) (4) . Interference with translation causes the production of erroneous proteins, and accumulation of mutant membrane proteins compromises the integrity of the bacterial envelope, which then allows the uptake of more aminoglycosides, resulting in further misreading and, eventually, cell lysis (5) . Other aminoglycosides, such as apramycin and spectinomycin, act in a different mode by inhibiting the translocation process (6, 7) .
Under physiological conditions, aminoglycosides are cationic. The importance of electrostatic interactions in specific binding between aminoglycosides and their anionic RNA targets has been well established (8, 9) . Binding of aminoglycosides to nonribosomal RNAs may contribute to their potential therapeutic applications but also to the side effects that are observed for this class of compounds. Serious side effects, including ototoxicity and nephrotoxicity, have been reported and have limited the clinical use of aminoglycosides.
Methods, such as surface plasmon resonance and fluorescence anisotropy, have been applied to probe the specificity of aminoglycoside-RNA interactions (10) (11) (12) (13) (14) . In general, specificity is measured by comparing the binding constants of chosen aminoglycosides against several related RNA sequences. These methods are fairly low-throughput because of their time-and materialconsuming nature. Approaches for a large-scale specificity evaluation, for example to test a given RNA-binding molecule against all RNAs presented in cells, would be valuable for therapeutic purposes and to further our understanding of small-molecule-RNA interactions.
The Human Genome Project has generated a massive amount of DNA sequence information. DNA microarray technology is one of the tools developed to take full advantage of this information to analyze the structure and function of tens of thousands of genes at a time. It has become an important research tool and is beginning to be used in diagnostic and clinical applications (15) (16) (17) (18) . Here we report the use of DNA microarray technology to evaluate smallmolecule-RNA binding on a large scale. Two approaches for applying DNA arrays were investigated (Fig. 1) . The first approach used aminoglycoside-coated magnetic beads to pull out specific aminoglycoside-binding RNAs from cellular mRNA samples. DNA microarrays were then used to identify bound RNA species. The second approach was to add the aminoglycoside directly to the hybridization reaction between RNA samples and the DNA probes on the array and compare the results with those from a control experiment without added small molecules. Differential hybridization suggests a possible interaction between the small molecule and a specific RNA sequence. These methods differ from traditional DNA array experiments because the readout is a direct measure of the interaction between mRNA and a ligand, rather than an indirect measure of effect on expression.
Results and Discussion
Magnetic Bead Capture. Tobramycin was used for this study. The 6Љ position was chosen as a site of covalent immobilization because biochemical and structural studies have indicated that this position is not directly involved in binding to 16S A-site rRNA; therefore, attachment to the bead through a linker at this position would not interfere with binding specificity (19, 20) . Magnetic beads were chosen as the conjugate solid support because of their ease of handling and separation. We attached the small molecule to the magnetic beads in two different ways. One method linked the beads through the aforementioned 6Љ-position of tobramycin. The other method used random attachment of the beads to any amine functional group of the molecule. This allowed tobramycin to be displayed in multiple orientations on the beads for the potential discovery of new RNA-binding motifs. For the first attachment strategy (Scheme 1), tobramycin 1 was modified to add an aminoterminal linker at the 6Љ position by following reported procedures (21) (22) (23) . The resulting Boc-protected tobramycin derivative 2 was coupled to carboxyl-terminated magnetic beads by using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide according to the protocol provided by the supplier. Deprotection provided the magnetic-bead-conjugated tobramycin 3. For the second immobilization strategy, tobramycin 1 was directly coupled to the carboxylterminated magnetic beads by following the protocol described above to give beads with a random distribution of conjugated tobramycin 4. As negative controls, beads conjugated with Dglucosamine 5, and with an amine-containing ␣-fucosidase inhibitor, fuconojirimycin 6, (24) also were prepared (Fig. 2) .
As a model study to test the ability to detect specific binding with tobramycin-linked beads, we used fluorescein-labeled 16S A-site rRNA, a known specific target of tobramycin (8) . We analyzed the fluorescence of beads 3-6 and control beads with no aminoglycoside after a sequence of washes with buffer (50 mM Tris⅐HCl͞150 mM NaCl͞4 mM MgCl 2 ͞1% BSA, pH 7.5) (Fig. 3) . In all cases, we were able to efficiently wash away the nonspecifically bound RNA on control and unmodified beads after several washes. Tobramycin linked to the magnetic beads at the 6Љ-position (compound 3) and randomly conjugated at various amine positions (compound 4)
were both able to retain specifically bound RNA after several washes. The two control molecules, 5 and 6, which should not bind appreciably to RNA, were also found to be effectively washed under the same conditions (Fig. 3) . The specifically bound RNA could be desorbed from the beads and recovered by elution with 1 M potassium acetate (25) , followed by coprecipitation with linear acrylamide and ethanol (26) .
After optimizing binding conditions in the model system, we proceeded to use the tobramycin-bound beads to identify specifically bound RNAs from a cellular extract, and use DNA arrays to identify their sequences. Total cellular RNA consists mostly of ribosomal RNA, which would likely saturate all tobramycin sites on the beads. Therefore, we used an mRNA extract from human liver, purified by taking advantage of the polyA tail of mRNA. Commercial human liver polyA RNA was incubated with compound 3 or 4, as well as unmodified magnetic beads as a control, at room temperature for 10 min. After three washes with wash buffer (50 mM Tris⅐HCl͞150 mM NaCl͞4 mM MgCl 2 ͞1% BSA, pH 7.5), 1 M KOAc was used to recover 
Scheme 1.
Synthesis of magnetic-bead-conjugated tobramycin 3. a, (Boc) 2O͞NEt3͞DMF͞H2O; b, 2,4,6-triisopropylbenzenesulfonyl chloride͞ pyridine; c, cysteamine hydrochloride͞NaOMe͞MeOH, (40%, 3 steps); d, 2% 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide͞10 mM KH 2PO4͞150 mM NaCl, pH 5.5; e, TFA͞dichloromethane. specifically bound RNA on the beads. The recovered RNA was purified by coprecipitation with linear acrylamide by following standard procedures. The coprecipitated RNA was then reversetranscribed, amplified, labeled, and analyzed with standard Affymetrix protocols to identify sequences from the human transcriptome that bound specifically to the tobramycin beads. Each experiment was repeated to ensure reproducibility.
For both experiments using beads 3 and 4, the vast majority of genes were not represented on the arrays, as expected. Using a cutoff of a 2.0 signal log ratio increase relative to the blank bead control, which corresponds to a 4-fold greater signal, compound 3 pulled out 216 genes, or Ϸ0.4% of the total, and compound 4 pulled out 1,164 genes, or 2.0%. Significantly, only 25 genes were scored as present in the experiment with compound 3 but absent with compound 4. Therefore, almost all of the hits with compound 3 were also hits with compound 4. In general, compound 4 was expected to pull out more genes than compound 3, given that it makes more orientations of tobramycin available for binding due to its random attachment method. The complete list of genes for both experiments is available in the Gene Expression Omnibus database under accession number GSE5111. Although some of the hits observed in these experiments are expected to be highly expressed in the liver and may simply represent nonspecific retention of the most abundant mRNAs in each experiment, other hits are clearly not highly abundant mRNAs. Each hit must be validated by independent binding experiments to distinguish those that result from specific, high-affinity binding to tobramycin.
When the cutoff was set to a more stringent signal log ratio of 5.0 (a 32-fold greater signal relative to control), compound 3 pulled out a total of 26 genes. Significantly, 21 of the 26 genes also had a signal log ratio of 5.0 or higher in the experiment with compound 4 (Table  1) . Clearly, common motifs were recognized by both types of tobramycin beads. Although specific sequence motifs and threedimensional structures that bind to tobramycin cannot be predicted solely from these data, it provides a small set of sequences that can be probed biochemically, through surface plasmon resonance and footprinting experiments, to determine new specific aminoglycoside-binding RNA motifs. The data may also be relevant for deducing the molecular basis of side effects observed during clinical treatment with these compounds.
Direct Hybridization Interference Method. The second approach to high-throughput analysis of small-molecule-RNA binding specificity was to add the ligand directly to the hybridization reaction between RNA samples and DNA probes on the array and compare to the results obtained in the absence of ligand (Fig. 4) . Each hybridization interference would suggest possible small-molecule-RNA interactions. This label-free approach eliminates unwanted effects introduced by structural modifications to the ligand.
We first used a simple model system to test whether RNAbinding small molecules would be able to disrupt hybridization between a target RNA and its complementary DNA probe on a glass slide (Fig. 5) . Two RNA sequences were chosen as targets. One was the aforementioned FITC-labeled 27-nt 16S A-site rRNA and the other was Cy3-labeled polyA, also 27 nt in length. The polyA RNA sequence was chosen as a negative control because of its presence in all mRNA sequences. The complementary DNA sequences were spotted in various concentrations onto polylysinecoated glass slides.
After we demonstrated hybridization of fluorescent RNA corresponding to the complementary DNA probes on the glass slides, we added RNA-binding molecules to see whether they would be able to disrupt the hybridization and whether the interference could be detected. Two RNA-binding molecules, neomycin B and streptomycin, with different binding affinities toward the A-site RNA, were tested. The dissociation constant of neomycin B against the 16S A-site RNA is reported to be 200 nM, and that of streptomycin is 94 M, or Ϸ500-fold weaker. A water-only blank and a serial concentration of the aminoglycosides from 10 nM to 100 M were added to either FITC-A-site RNA or Cy3-polyA RNA and incubated for 10 min at room temperature before transferring the mixtures onto each grid on the glass slide to hybridize with the DNA probes. The hybridizations were carried out at room temperature for 1 h with gentle shaking. The glass slides were then washed with 500 mM NaCl to remove unhybridized RNA. After drying, the slides were analyzed by using a slide reader, and the fluorescence signals in the images were quantified (Fig. 6) . The binding affinity of the two aminoglycosides toward the 16S A-site RNA was reflected in the ability of these two molecules to disrupt RNA-DNA hybridization, as indicated by the decrease in fluorescence signal observed after adding neomycin B and streptomycin.
The hybridizations were disrupted in both cases when high concentrations of molecules were added, but differences were observed at lower concentrations, reflecting the known specificities of the two aminoglycosides. Neomycin B also showed better ability to disrupt the hybridization between the A-site RNA and its DNA probe than between polyA RNA and its complementary DNA sequence on the slide, as expected based on its specificity for A-site RNA (Fig. 7) . Again, at high concentrations of neomycin B, the disruption of hybridization was observed in both cases, probably because of nonspecific interactions with RNA. Streptomycin, a weaker A-site binder, showed lower levels of hybridization interference and similar levels of disruption for both A-site RNA and polyA RNA hybridizations, consistent with a lack of specificity. Having shown that it was possible to use small molecules to affect the hybridization of RNA to its complementary DNA and that the level of interference correlated to its binding affinity to that RNA, we next used DNA arrays for a large-scale analysis of which RNA sequences were bound to the tested small molecule. By comparing the fluorescent hybridization signal changes in the presence of a small molecule to signals obtained in the absence of the molecule, we identified RNAs for which the aminoglycoside interfered with the hybridization. As for the bead experiments, human liver mRNA was used in this study. Standard DNA array procedures were performed, except for the addition of 5 M neomycin B or tobramycin. The results of the hybridization experiments were analyzed with standard protocols to average the probe set of each gene to give lists of affected genes. For neomycin B, 17 genes were found to have a signal log ratio reduction of 2.0 or greater. For tobramycin, there were 18 genes ( Table 2 ).
In addition to these genes, which exhibited significantly reduced hybridization, a few genes showed slightly increased hybridization (see accession GSE5111 in the Gene Expression Omnibus database). Both scenarios indicate that the presence of the small molecules interferes with hybridization. In the case of increased hybridization signal, the aminoglycoside may bind to and stabilize the double-helical complex between RNA and the DNA probe on the chip. Identification of DNA-RNA duplex structures that are specifically bound and stabilized by ligands may be interesting as well. Reduced hybridization would occur because of formation of a complex between aminoglycoside and the RNA, preventing hybridization to the complementary DNA probe. Further analysis of the data on the level of individual DNA probes rather than the average of the probe sets may provide more information on the exact binding sites on the RNAs. As with the magnetic bead method, the direct hybridization method provides a finite list of RNA sequences to be validated biochemically for specific RNA binding by using methods such as surface plasmon resonance and footprinting. A detailed analysis of the sequences pulled out by these methods showed no sequence homology between the hits or to the ribosomal A-site sequence. However, divergent sequences may have similar three-dimensional folds, which cannot be readily predicted based only on the sequence. Biochemical and structural analysis will be needed to identify common aminoglycoside-binding RNA folds that may be present in these sequences.
As previously noted, common hits were found in different experiments within the same method, for instance, between bead experiments with compounds 3 and 4. However, the two different methods (magnetic bead capture and direct hybridization interference) did not have common hits between them. One issue with hybridization interference that may affect binding results is due to the nature of the microarray technology. The RNA contains covalently attached fluorescent tags that may affect its folding dynamics, structure, and ligand-binding properties. In addition, there is a fundamental difference between the bead-based and hybridization methods. Whereas the bead-based method simply detects binding of native mRNA to the bead-tethered ligand, hybridization detects a competition between binding of the fluorescently tagged RNA, which has been denatured before binding, to a small-molecule ligand or to a complementary DNA oligonucleotide. It remains to be seen which method proves to be most useful for discovering new RNA-ligand binding motifs; the two methods may prove to be complementary to each other. We also believe that the general concept of using DNA microarrays for high-throughput binding specificity studies may be applied not only to RNA-binding ligands but also to DNA-binding ligands.
These studies are expected to result in the discovery of aminoglycoside-binding RNA motifs that may have physiological relevance related to their antibiotic activity and of the side effects that arise from treatment with these compounds. It is clear that the biological activity of aminoglycosides can arise from interactions with targets other than ribosomal RNA, as shown recently by their potent inhibition of Bacillus anthracis Lethal Factor protease activity (27) . Future efforts should be focused on the detailed characterization of sequences identified in this work to identify new RNA motifs and their interactions with small-molecule ligands.
Materials and Methods
All reagents were handled to minimize RNase contamination. The working area was pretreated by RNase Zap (Ambion, Austin, TX) to inactivate any ribonuclease present. Aminoglycoside solutions were made in diethyl pyrocarbonate-treated water (Ambion) or Milli-Q water (Millipore, Billerica, MA) and stored in RNase-free microfuge tubes (Ambion). The fluorescent-labeled RNA used in this study was purchased from Dharmacon Research (Lafayette, CO) and was 2Ј-O-bis(2-acetoxyethoxy)methyl protected. Deprotection was performed according to the supplier's protocol. The BcMag carboxylterminal magnetic beads and the magnetic separator were purchased from Bioclone (San Diego, CA). Nunc (Rochester, NY) black fluorescent 96-well plates were pretreated with RNase Zap, rinsed with fresh Milli-Q water, and dried before use. Human liver poly(A) RNA and linear acrylamide (5 mg͞ml) and were ordered from Ambion. 5Ј-amino-modified DNA oligonucleotides were ordered from Allele Biotech (San Diego, CA). DNA microarrays were purchased from Affymetrix (Santa Clara, CA).
General Procedures for Immobilization of Small Molecules onto Mag-
netic Beads. A suspension of 0.5 ml of BcMag carboxyl-terminal magnetic beads (4.8 mol͞ml) was transferred to a 2-ml centrifuge tube, and 1 ml of coupling buffer (10 mM potassium phosphate, mono basic͞150 mM NaCl, pH 5.5) was added. The mixture was shaken vigorously and then inserted into a magnetic separator and allowed to stand until the supernatant was clear. The supernatant was aspirated and discarded. The washing steps were repeated three times. The particles were then resuspended into 0.5 ml of coupling buffer. A solution of immobilized small molecules in 0.5 ml of water (5 eq) and 0.25 ml of 2% 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide in water were added, and the mixture was shaken at room temperature for 24 h. The pH was maintained between 4.5 and 6.0 with 0.1 M HCl during the reaction. When the reaction was finished, supernatant was removed as described. The modified beads were then washed with wash buffer (10 mM Tris base͞150 mM NaCl͞0.1% BSA͞1 mM EDTA͞0.1% NaN 3 , pH 7.5) three times, RNase Zap-treated Milli-Q water two times, Milli-Q water three times, and HBS buffer two times. The resulting beads were resuspended in HBS buffer (250 l) and stored at 4°C. The three genes in common from the neomycin B and tobramycin experiments are shown in bold. Entries in bold also showed reduced hybridization in the presence of 5 M neomycin B. -, unknown.
General Procedures for Measuring Binding Between RNA and Small
Molecules on Beads. To the small molecule-conjugated magnetic beads (or unmodified beads), in 20 l of HBS buffer (Ϸ192 nmol) in an RNase-free centrifuge tube, was added 10 l of 10 M FITC-16S-A-site RNA (Ϸ1 g), and the mixture was gently shaken for 10 min at room temperature. The supernatant and the beads were separated by a magnetic separator. Wash buffer was added to resuspend the beads, and part of the suspension (5 l) was transferred to a 96-well plate for fluorescence measurements on a Fusion Universal Microplate Analyzer (PerkinElmer, Wellesley, MA). Washing procedures were repeated several times as indicated. For obtaining RNA for array analysis, 100 l of buffer (50 mM Tris⅐HCl͞150 mM NaCl͞4 mM MgCl 2 ͞1% BSA, pH 7.5) was used in each wash step, and 100 l of 1 M KOAc was used in each desorption step. Three washes and three desorptions were performed. The RNA solution obtained from regeneration steps (300 l in 1 M KOAc) was diluted with 696 l Milli-Q water, and then 4 l of linear acrylamide was added to a final concentration of 20 g͞ml. The mixture was agitated, and 1 ml of EtOH was then added and cooled at Ϫ80°C for 1 h, then centrifuged at 13,200 ϫ g at 4°C for 30 min. The supernatant was removed, and the pellet was washed with 80% EtOH and then centrifuged again at 13.200 rpm at 4°C for 10 min. The supernatant was removed, and the pellet was dried on a speedvac. The RNA was then redissolved in an appropriate amount of Milli-Q water and stored at Ϫ80°C for the later amplification steps, which used an Ambion MessageAmp II aRNA Amplification kit, followed by standard Affymetrix DNA array methods.
General Procedures for Immobilization of DNA Probes on Glass Slides.
DNA probes complementary to the target RNA sequences were spotted onto poly-lysine-coated glass slides using an automated glass slide spotter. The DNA samples were spotted at concentrations of 32, 16, 8, 4, 2, and 1 M. A blank sample without DNA also was spotted as a negative control. In each grid on a glass slide, seven replicates of each concentration were spotted in each row. After DNA immobilization, glass slides were blocked with succinic anhydride. A freshly prepared solution of 6 g of succinic anhydride in 330 ml of 1-methyl-2-pyrrolidinone and 15 ml of 1 M sodium borate (pH 8) was poured into an empty slide chamber. The glass slides with arrayed DNA samples were placed in the slide rack and plunged rapidly and evenly in the succinic anhydride solution. The slide rack was shaken gently on an orbital shaker for 20 min. The slide rack was then placed into 95°C water for 2 min and plunged five times in 95% ethanol. The glass slides were air dried and stored in a desiccator.
General Procedures for Hybridization Experiments on Glass Slides.
The border of each grid on the glass slides was first marked with a hydrophobic marker to constrain the aqueous sample in the grid and prevent contamination with other samples. Samples of either FITC-A-site RNA or Cy3-polyA RNA (70 l) in 500 mM NaCl, with or without added aminoglycoside, were prepared in microcentrifuge tubes or a 96-well microtiter plate. Of the mixed solution, 35 l was then transferred to each corresponding grid on the glass slide. Samples containing added aminoglycoside were incubated for 10 min at room temperature before transfer. The resulting glass slide with samples was placed in a humidifying chamber and covered with aluminum foil to prevent incident light. The chamber was shaken gently on an orbital shaker at room temperature for 1 h. After the hybridization was finished, the slide was washed by immersion twice with 500 mM NaCl and twice with 250 mM NaCl. The slide was dried by air stream, and fluorescence scans were then performed on the slide reader. The resulting images were analyzed with the program Imagene to locate and quantify the fluorescence signals of all spots in each grid.
DNA Array Experiments. Affymetrix Human Genome U133 Plus 2.0 arrays were used in these studies. DNA array experiments with or without small molecules added were performed according to standard Affymetrix DNA array protocols. The final concentration of added neomycin B and tobramycin was 5 M. Data processing of the hybridization results were performed according to standard analysis protocols by using the NetAffx Analysis Center on the Affymetrix web site.
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